Analyst Price Target is $35.50
▲ +6.35% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Lakefront Biotherapeutics American Depositary Shares in the last 3 months. The average price target is $35.50, with a high forecast of $45.00 and a low forecast of $26.00. The average price target represents a 6.35% upside from the last price of $33.38.
Current Consensus is
Hold
The current consensus among 8 polled investment analysts is to hold stock in Lakefront Biotherapeutics American Depositary Shares. This rating changed within the last month from a Moderate Buy consensus rating.
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Read More
